Publications by authors named "Leah Pirondini"
Article Synopsis
- Aspirin is the only recommended antiplatelet drug for long-term cardiovascular event prevention in patients with coronary artery disease (CAD), but its effectiveness compared to other drugs, like P2Y inhibitors, is unclear.
- This study evaluated whether P2Y inhibitor monotherapy is more effective than aspirin for preventing heart issues in CAD patients by analyzing data from multiple trials involving over 24,000 participants.
- Results showed that P2Y inhibitors led to fewer major heart problems and similar bleeding risks compared to aspirin, suggesting they may be a better option for long-term treatment in CAD patients.
Background: Acute kidney injury (AKI) is a frequent complication in patients with severe respiratory failure receiving extracorporeal membrane oxygenation (ECMO). However, little is known of long-term kidney function in ECMO survivors. We aimed to assess the long-term mortality and kidney outcomes in adult patients treated with veno-venous ECMO (VV-ECMO).
View Article and Find Full Text PDFBackground: Socioeconomic deprivation is associated with higher cardiovascular morbidity and mortality. Whether deprivation status should be incorporated in more cardiovascular risk estimation scores remains unclear. This study evaluates how socioeconomic deprivation status affects the performance of 3 primary prevention cardiovascular risk scores.
View Article and Find Full Text PDFIn randomized controlled trials, patient characteristics are expected to be well balanced between treatment groups; however, adjustment for characteristics that are prognostic can still be beneficial with a modest gain in statistical power. Nevertheless, previous reviews show that many trials use unadjusted analyses. In this article, we review current practice regarding covariate adjustment in cardiovascular trials among all 84 randomized controlled trials relating to cardiovascular disease published in the New England Journal of Medicine, The Lancet, and the Journal of the American Medical Association during 2019.
View Article and Find Full Text PDFBackground: There are limited data on acute kidney injury (AKI) progression and long-term outcomes in critically ill patients with coronavirus disease-19 (COVID-19). We aimed to describe the prevalence and risk factors for development of AKI, its subsequent clinical course and AKI progression, as well as renal recovery or dialysis dependence and survival in this group of patients.
Methods: This was a retrospective observational study in an expanded tertiary care intensive care unit in London, United Kingdom.